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Abstract
Objective: To assess the feasibility of using synthetic computed tomography for treatment planning of the dominant intraprostatic lesion (DIL), a high-risk region of interest
that offers potential for increased local tumor control.
Methods: A dosimetric study was performed on 15 prostate cancer patients with
biopsy-proven prostate cancer who had undergone magnetic resonance imaging. DILs
were contoured based on the turbo spin echo T2-weighted and diffusion weighted
images. Air, bone, fat, and soft tissue were segmented and assigned bulk-density HU
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values of –1000, 285, –50, and 40, respectively, to create a synthetic computed tomography. Simultaneous integrated boost (SIB) and standard treatment plans were created
for each patient. The total dose was 79.2 Gy to the non-boosted planning target volume
for both plans with a boost of 100 Gy for the DIL in the SIB plan. A radiobiological model
was created to determine individualized dose–response curves based on the patient’s
apparent diffusion coefficient maps.
Results: Mean doses to the non-boost planning target volume were 81.2 ± 0.3 Gy
with the SIB and 81.0 ± 0.4 Gy without. For the DIL, the boosted mean dose was
102.6 ± 0.6 Gy. Total motor unit was 860 ± 100 with the SIB and 730 ±100 without.
Femoral heads, rectum, bladder, and penile bulb were within established dose guidelines for either treatment technique. The average tumor control probability was 94%
with the SIB compared with 78% without boosting the DIL.
Conclusion: This study showed the feasibility of magnetic resonance imaging-only
treatment planning for patients with prostate cancer with a SIB to the DIL. DIL dose
can be escalated to 100 Gy on synthetic computed tomography, while maintaining the
original 79.2 Gy prescription dose and the organ of interest clinical dose limits.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any
medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
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1

INTRODUCTION

scans. An experienced radiologist delineated the prostate and DIL contours for each patient using the MP-MRI. A 5-mm margin was added

Pathological studies have shown that dominant intraprostatic lesions

to the prostate and the DIL, to create the planning target volumes

(DIL) play an important role in prostate cancer progression, and might

(PTVprostate and PTVDIL ).

post-treatment.1,2

MR images were acquired using an Ingenia 3.0 T magnetic

Curative options for localized prostate carcinoma, including surgery

resonance system (Philips Medical Systems, Best, the Nether-

and image-guided radiotherapy, have proven to be the standard of care

lands). Two MRI sequences were utilized to delineate the dom-

by effectively controlling localized disease. Various clinical trials (RTOG

inant intraprostatic lesions: 2-D turbo spin echo T2-weighted

0126) have shown improved tumor control with escalated radiation

imaging (TE /TR = 4389/110 ms, FA = 90◦ , voxel size = 0.42 ×

be considered the epicenter of local recurrence

dose to the entire

prostate.3,4

However, dose escalation increases the

treatment-related normal tissue complication probability (NTCP).

0.42 × 2.4 mm3 ) and DWI (TE /TR = 4000/85 ms, FA = 90◦ ,
voxel size = 1.79 × 1.79 × 0.56 mm3 , with b-values = 0 and

Multiparametric magnetic resonance imaging (MP-MRI) is an

1000 [s/mm2 ]).11 The 3-D GRE mDixon T1 image set (in-phase:

emergent standard of care for the detection of localized prostate

TE /TR = 2288/4067 ms, out-phase: TE /TR = 1116/4067 ms, FA = 12˚,

cancer. MP-MRI provides superior morphological and functional

voxel size = 0.63 × 0.63 × 1.9 mm3 ) was used to create the synthetic

information by blending T2-weighted imaging and diffusion-weighted

CTs for treatment planning. For three patients, the mDixon images

imaging (DWI). The combination of T2-weighted imaging and DWI

were rigidly registered to diagnostic CT image sets using the open-

has been shown to provide high sensitivity/specificity (performance

source software, Elastix (University Medical Center Utrecht, Utrecht,

0.8–0.9) in DIL identification, and has been recommended in current

the Netherlands), to fill in the superficial fat tissue.12,13 For a patient

consensus

guidelines.5,6

At the same time, the application of MRI in

without a diagnostic CT, the peripheral tissue was determined by

radiation oncology has grown. MRI offers excellent soft tissue contrast

extrapolating the boundary regions from the mDixon images. These

for target and organ delineation, and can track tumor motion during

regions were then assigned a HU value corresponding to fat (–50 HU).

treatment without extra radiation exposure or treatment interruption.

The synthetic CT generation is based on bulk density HU assignment

In addition, MRI can probe biological properties using diffusion or

to soft tissue, fat, bone, and air using the mDixon images. The advan-

perfusion imaging, and assess tumor and normal tissue response

tage of using the mDixon technique is the ability to derive fat-only and

during treatment. For example, apparent diffusion coefficient (ADC)

water-only images from the in-phase and out-phase sequences, sim-

maps can be correlated to clonogen cell density in the tumor. The

plifying the segregation of fat and soft tissue image components. In

evaluation of clonogen number changes over the treatment course

this approach, a k-means clustering algorithm is utilized to segment

can provide insights of local tumor control over time. However, MRI

soft tissue and fat.14 This algorithm divides n objects into k clusters

does not contain electron density information, which is essential for

by assigning each object to the cluster with the nearest mean value.

dose calculation. Multiple methods have been proposed to generate

Segmentation of bone and air in MR images is problematic due to the

synthetic computed tomography (CT). As DIL is small, in the order of

relative absence of acquired signal for both structures. For this reason,

a couple milliliters, geometric uncertainty is a key consideration in

the pelvic bones were manually contoured by an experienced physicist.

synthetic CT generation.

Bulk densities were assigned to air, bone, fat, and soft tissue (–1000,

The present study describes the development of a MRI-only work-

285, –50, 40 HU, respectively) as seen in Figure 1.15

flow using synthetic CT images generated from MR images for prostate

Treatment plans were created on synthetic CTs using Eclipse treat-

treatment planning incorporating a simultaneous integrated boost

ment planning software (Varian Medical Systems, Palo Alto, CA, USA)

(SIB) to the MP-MRI-defined DIL, while aiming to maintain standard

with two 360◦ arcs and high-definition multileaf collimator system.

prescription dose to the prostate gland (79.2 Gy) and keep the normal

Two treatment plans per patient were generated: a standard fraction-

tissue doses within established limits. The radiobiological model is used

ation prostate plan (PTVprostate 79.2 Gy in 44 fractions) and a SIB plan.

to compare the SIB approach and standard care by incorporating tumor

The SIB plan prescribed 79.2 Gy to the PTVprostate and 100 Gy to the

clonogenic cell density derived from the DWI.

PTVDIL in 44 fractions. This fractionation scheme is based on the focal
lesion ablative microboost in prostate cancer (FLAME) clinical trial.16
The organs at risk (OARs), including the rectum, bladder, femoral heads,

2

METHODS

and the penile bulb, were contoured on the mDixon images.
Using dose–volume histograms (DVH), D95, D99, and the maxi-

A retrospective dosimetric study was performed with 15 biopsy-

mum dose to the DIL and PTV were analyzed to assess dose cover-

proven prostate cancer patients that had undergone diagnostic MRI

age. The OAR constraints were based on NRG/QUANTEC protocols
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F I G U R E 1 (A) mDixon magnetic resonance image and (B) synthetic computed tomography (right) with femoral (pink), pelvic (orange), and
spinal bones (blue), planning target volume (red), prostate (green), dominant intraprostatic lesion (magenta), bladder (yellow), and rectum (brown)

for both plans.17,18 Namely, V70 and V75 were analyzed for the rec-

the most radiosensitive organ for prostate cancer treatments per

tum, to assess the risk of late rectal toxicity. V70 and V75 were ana-

QUANTEC.17 The values for the NTCP modeling are based on the

lyzed for the bladder, where observable symptoms are the end-point.

meta-analysis carried out by QUANTEC, where m (slope) is 0.13, n (vol-

For the femoral heads, D5 was calculated due to the risk of bone necro-

ume effects) is 0.09, dose where toxicity occurs in 50% of cases (TD50)

sis. Finally, the mean dose for the penile bulb was assessed as a result

is 76.9 Gy, and α/β for the rectum is 3 Gy.17,28 Rectal NTCP values

of severe erectile dysfunction risk.

were generated for both plans, with an end-point of grade ≥2 rectal

In addition to DVH comparisons, radiobiological modeling was used

bleeding.

to evaluate treatment outcomes. A linear Poisson tumor control probability (TCP) formulation was created and the Lyman–Kutcher–Burman
Model for NTCP was used.19,20 All calculations were performed using

3

RESULTS

BioSuite 12 (developed by Julian Uzan, NHS Clatterbridge Center for
Oncology, Birkenhead, UK).

Table 2 lists the PTV and OAR dose statistics for each planning tech-

Several studies investigated the α/β ratio for prostate cancer with

nique. The average PTVprostate D95 for the standard and SIB plans were

varying results.21–23 TCP values were determined using α/β = 1.93 Gy

similar at 99.1% of the prescription dose. Figure 2 shows the location of

based on the meta-analysis of Vogelius and Bentzen.24 A key aspect of

the global maximum. For the SIB plan, the average maximum dose was

TCP modeling is the clonogen density. ADC values are known to have

(105.5 ± 1.2) Gy.

a significant negative correlation with clonogen density in prostate

All OAR doses were within QUANTEC constraints for prostate

cancer.25 We therefore adopted a method developed by Casares-

treatment. No significant difference (p > 0.05) was observed for the

Magaz et al. to calculate clonogen density, wherein the clonogen den-

dose statistics between the standard and SIB plans. The rectal V75

sity for the DIL was based on average ADC values inside the lesion,

was (7.5 ± 2.3)% for the standard plan and (7.2 ± 2.3)% for the SIB

105

plan. For the bladder, the V75 was (8.9 ± 3.9)% for the standard plan

clonogens per cm3 .26 The patient ADC information, calculated clono-

and (8.6 ± 3.8)% for the SIB plan. The maximum dose for the rectum

whereas the rest of the prostate was given a constant density of

gen density, and the DIL volume are tabulated in Table 1. The overall

and bladder were <85 Gy for each plan. Figure 3 shows the DVHs for

TCP for the prostate was calculated by multiplying the DIL’s TCP with

patient 9 as a typical example. For patient 9, the D95 for the PTV were

the TCP for the remaining volume of the prostate.

slightly higher for the standard plan (79.4 Gy vs. 78.7 Gy for D95). The

Another consideration for radiobiological modeling was tumor

rectum and femoral heads DVH were slightly lower for the SIB over the

regrowth. This is incorporated into the linear quadratic model by the

standard plan, whereas, the bladder dose increased for SIB plan. This

repopulation correction factor, which is calculated as exp(ln(2) ⋅ T∕Teff ),

was due to the shallower shoulder of the PTVprostate DVH on the SIB

where T is the total treatment duration and Teff is the effective dou-

plan.

bling time of the tumor. An onset time, Tk , is also applied, as clonogen

Further analysis showed that patient 7 exhibited the lowest PTV

repopulation does not typically occur immediately. All TCP calculations

and DIL D95 for the SIB plan (DIL D95 of 99.5 Gy and PTV D95 of

were performed with Teff = 28 days and Tk = 30 days.26,27

77.3 Gy). This patient also received the highest rectal dose, as the DIL

For NTCP calculations, the Lyman–Kutcher–Burman model was

was located in close proximity to the rectal interface. This led to a

implemented to find the NTCP for the rectum, which is considered

high dose to the rectum in both plans, while negatively impacting the
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Dominant intraprostatic lesion volume, average apparent diffusion coefficient value, and the calculated clonogen density for each

Patient no.

DIL volume
(cm3)

Average ADC DIL
(10–6 mm2 /s)

Standard
deviation

Clonogen density
(108 /cm3 )

1

1.15

1570

92

4.4

2

0.06

814

310

10.8

3

0.88

710

108

11.6

4

0.09

1118

205

8.2

5

0.04

1343

165

6.3

6

0.01

918

228

9.9

7

0.09

746

207

11.3

8

0.22

1100

206

8.4

9

0.14

704

116

11.7

10

0.11

1337

190

6.4

11

0.11

1120

189

8.2

12

0.21

1318

230

6.5

13

0.19

1016

176

9.1

14

0.16

1250

180

7.1

15

3.19

790

194

11.0

ADC, apparent diffusion coefficient; DIL, dominant intraprostatic lesion volume.

TA B L E 2 Dose statistics for the standard plan and the
simultaneous integrated boost plan
Standard
PTVProstate

DIL

Rectum

Bladder

Femoral heads

Penile bulb

D95 (Gy)

78.5 ± 0.6

plan, and (860 ± 100) MU for the SIB plan. This trend was expected
due to the higher dose to PTVDIL and the increased multileaf collima-

SIB

tor modulation.
The average TCP dose–response curves along with the 95% confi-

78.5 ± 0.6

dence intervals for the prostate and DIL are shown in Figure 4. The

Mean Dose (Gy)

81.0 ± 0.4

81.2 ± 0.3

D95 (Gy)

80.8 ± 1.2

100.5 ± 0.5

Mean Dose (Gy)

80.9 ± 1.2

102.6 ± 0.6

Max. Dose (Gy)

83.8 ± 0.6

83.9 ± 0.7

Mean Dose (Gy)

31.2 ± 5.2

30.9 ± 4.4

Rectal NTCP results are tabulated in Table 2. The average rectal

V70 (%)

9.9 ± 2.8

9.8 ± 3.2

NTCP was 6.2% (95% CI 5.2%–7.3%) for the standard plan and 5.3%

V75 (%)

7.5 ± 2.3

7.2 ± 2.3

(95% CI 4.5%–6.5%) for the SIB plan. The maximum NTCP (9.8%) was

NTCP (%)

6.2 ± 2.1

5.3 ± 1.7

observed in patient 3. This is may be caused by the higher hotspot in

Max. Dose (Gy)

83.8 ± 0.8

83.7 ± 0.9

Mean Dose (Gy)

36.2 ± 8.9

35.4 ± 7.8

V70 (%)

11.5 ± 4.8

11.3 ± 4.7

V75 (%)

8.9 ± 3.9

8.6 ± 3.8

Max. Dose (Gy)

38.5 ± 6.3

39.3 ± 9.5

Pilot studies have shown that the administration of a boost dose to the

D5 (Gy)

29.6 ± 6.1

29.6 ± 8.3

DIL increases the probability of tumor control.29–33 Simultaneous dose

7.7 ± 5.9

7.9 ± 4.9

escalation to the DIL without an increase in the risk of late compli-

Mean Dose (Gy)

DIL, dominant intraprostatic lesion volume; PTV, planning target volume;
SIB, simultaneous integrated boost.

average TCP for the DIL was 99% at 100 Gy, compared with 83% at
79.2 Gy. The overall TCP of (94 ± 2)% for the SIB plan was a sizeable
improvement relative to the non-SIB TCP of (79 ± 9)%. Lowering the
average PTVDIL dose to 88.5 Gy would still achieve a DIL TCP of 98%.

the PTVprostate , allowing for less dose falloff to the rectum.

4

DISCUSSION

cations has the potential to improve local tumor control for prostate
cancer patients. To achieve this, it is critical to accurately delineate
the DIL, boost the dose to DIL without compromising the OARs, and
predict the clinical outcome in the early stages of planning. We devel-

PTVprostate and PTVDIL dose coverage in the boost plan; however, the

oped an MRI-only workflow to define the DIL on MP-MRI images,

rectal dose was kept within the QUANTEC tolerances.

delineate prostate and OARs on morphological MR images, gener-

The total MU were 18% greater for the boost plans relative to the

ate synthetic CT from mDixon images for dose calculation, and gen-

standard plans. The averages were (730 ± 100) MU for the standard

erate an individualized radiobiological model incorporating clonogen
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F I G U R E 2 (A,B) Axial, (C,D) coronal, and (E,F) sagittal slices of the dose distribution for patient 9 (A,C,E) with and (B,D,F) without simultaneous
integrated boost
density directly derived from ADC maps to assess patient therapeutic

methods.14,34,35,36 For voxel-based conversion, voxel values from MR

ratios.

images are used to calculate CT voxel values. Atlas-based synthetic

Initial efforts to incorporate MRI in treatment planning used

CTs require a set of co-registered CT and MR images to create a set of

registration to the CT simulation image set and propagation of the

co-registered atlases that can be deformably registered to a patient’s

MRI-derived contours to the CT images used for dose calculations.

MR images. Machine learning synthetic CTs are created based on

Several approaches have been proposed to improve image registration

algorithms trained from a set of MR-CT registrations. The generative

between MRI and CT in the pelvic region, including the thin-plate

adversarial network is currently the most popular machine learning

spline algorithm, landmark method, and biomechanical models, but an

algorithm. These methods may lead to geometrically accurate syn-

intrinsic deficiency in delineating prostate boundaries on CT images

thetic CTs, but some issues are present with the approaches. One issue

makes deformable image registration challenging.7–10

Considering the

for the voxel-based conversion method is an inability to handle the lack

small DIL sizes, MRI-to-CT contour propagation based on deformable

of consistency between voxel values across MRI scans for a specific

image registration could introduce geometrical errors that compro-

tissue type. Sufficient variability between voxel values of a specific

mise this strategy’s efficacy. For these reasons, a method of prostatic

tissue prevents adequate optimization of assigned weights, resulting

radiation treatment with simultaneous boost doses to the DIL solely

in inaccurate HU values for the synthetic CT. The use of mDixon

using MRI would be desirable.

images results in weights that are not accurate for the entire image set,

Approaches for developing synthetic CTs from MRI include

rendering this method impractical for our approach. The atlas-based

voxel-based conversion, atlas-based, and machine learning-based

and generative adversarial network algorithm-based methods require
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F I G U R E 3 The simultaneous integrated boost (solid lines) and standard plan (dashed lines) dose–volume histograms for patient 9. DIL,
dominant intraprostatic lesion; PTV, planning target volume

an extensive set of patients with both CT and MR images to generate
a synthetic CT atlas or MR-CT training set.35,36 If the set is not large
enough, the models will not be able to accurately generate synthetic
CTs. Another issue is registration errors between the CT-MR training
set will propagate into the models, leading to inaccuracies in the
synthetic CTs. This is one of the limitations of generative adversarial
network-based methods, as it still needs perfectly registered MRI and
CT training pairs for image synthesis, which is difficult to achieve in the
pelvic region with large organ deformations. Additionally, several studies have investigated the dosimetric accuracy of bulk density assigned
synthetic CTs. They showed a dose uncertainty of <1.5%.15,37,38 For
this reason, it was determined that bulk density synthetic CTs, while
not as accurate as the voxel-based conversion or atlas-based methods,
were the most viable option for treatment planning. Although we
noted that our reported method incorporated CT images to fill in the
excluded periphery of the acquired mDixon images in three patients, a
future adjustment to the MRI protocol to include skin-to-skin coverage
of all patients would mitigate this step and allow a complete MRI-only
workflow with more accurate synthetic CTs.
With respect to TCP, the best DIL result for the standard plan was
for patient 6, with 96% TCP due to a small lesion size. Patient 6′s PTVDIL
was 1.37 cm3 , the smallest treatment volume of the patient cohort. A
small lesion can result in high TCP, even without boosting the dose. This
F I G U R E 4 Tissue complication probability (TCP) dose–response
curves for (A) the standard and (B) the simultaneous integrated boost
plans. The solid line represents the mean curves and the dashed lines
represent the upper and lower 95% confidence interval. DIL,
dominant intraprostatic lesion; PTV, planning target volume

implies that although clonogen density plays a role, TCP also depends
on the lesion volume. Small lesions can be controlled more easily, independent of clonogen density; however, the correlation between the
lesion size and clonogen density is complicated and requires further
investigation. Patient 1 had a larger lesion (1.15 cm3 ) than patient 3
(0.88 cm3 ), but did not experience lower TCP due to clonogen density
(75% TCP vs. 67% TCP for the standard plan).
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Currently, there is not a consensus on the Teff and Tk values in the
TCP modeling for prostate cancer. Previous studies have shown variability in Teff values: from as little as 0 days to 62 days.26,39–42 These

2.

studies have shown that Teff is dependent on the cancer type and staging, and could potentially be different for individual cells of the same
cancer type. It is possible that Teff is unique for each individual, necessitating the calculation of Teff for every patient.43 Further investigation

3.

into Teff for prostate cancer is warranted, but for the present study,
the value of 28 days was deemed accurate for ‘medium’ proliferation.
For Tk values, there is less variability among published data, where
the typical value is approximately 28–34 days.21,27,40

4.

The chosen Tk of

30 days serves as a reasonable value for biopsy-proven prostate cancer
(stage T1c).27 Some studies have incorporated immediate onset time

5.

(Tk = 0); however, this is not considered accurate and would result in
low TCP values.21

6.

We observed no significant difference in the rectal V70 and V75
between the standard and SIB plans. The rectal NTCP results showed
significance, but followed the same trend as the rectum DVH. This
result is unexpected with the presence of the boost dose. However,

7.

this could be produced by slight differences in plan optimization that
do not show significance in the plan statistics, but nevertheless, affect

8.

the NTCP. In addition, DILs more commonly occur in the peripheral
zone, often near the rectal interface, resulting in a high dose to the
rectum.44–46 Considering the present rectum DVH and NTCP results,

9.

we showed that it is possible to produce clinically acceptable MRI-only
based treatment plans by boosting the dose to DIL, while maintaining

10.

prescription dose coverage to the PTV and dose constraints to rectum.
11.

5

CONCLUSION

We have shown a feasible implementation of MRI-only treatment plan-

12.

ning for prostate cancer with a SIB for DIL. The dose to the DIL can
be escalated to 100 Gy on the synthetic CTs, while maintaining the

13.

original prescription of 79.2 Gy and remaining within clinical criteria
for the OARs. The boost dose can be lowered to approximately 90 Gy

14.

and maintain high TCP based on the generated dose response curves.
Although the rectal NTCP shown differences between the SIB and
standard plan, this is not considered clinically significant. Further investigation into the creation and optimization of the synthetic CT and mar-

15.

gin for the DIL structure is warranted. If promising results are achieved,
a prospective study will be implemented.

16.

CONFLICT OF INTERESTS
No conflict of interest has been declared by the author(s).

17.

ORCID

18.

Ning Wen

https://orcid.org/0000-0001-9776-8056
19.

REFERENCES
1. Mouraviev V, Villers A, Bostwick DG, Wheeler TM, Montironi R,
Polascik TJ. Understanding the pathological features of focality, grade

and tumour volume of early-stage prostate cancer as a foundation
for parenchyma-sparing prostate cancer therapies: active surveillance
and focal targeted therapy. BJU Int. 2011;108(7):1074-1085.
Pucar D, Hricak H, Shukla-Dave A, et al. Clinically significant prostate
cancer local recurrence after radiation therapy occurs at the site of primary tumor: magnetic resonance imaging and step-section pathology
evidence. Int J Radiat Oncol Biol Phys. 2007;69(1):62-69.
Dearnaley DP, Sydes MR, Graham JD, et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first
results from the MRC RT01 randomised controlled trial. Lancet Oncol.
2007;8(6):475-487.
Zietman AL, DeSilvio ML, Slater JD, et al, . Comparison of
Conventional-Dose vs High-Dose Conformal Radiation Therapy
in Clinically Localized Adenocarcinoma of the Prostate. JAMA.
2005;294:(10):1233-1239.
Barentsz JO, Richenberg J, Clements R, et al. ESUR prostate MR guidelines 2012. Eur Radiol. 2012;22(4):746-757.
Dickinson L, Ahmed HU, Allen C, et al. Scoring systems used for the
interpretation and reporting of multiparametric MRI for prostate cancer detection, localization, and characterization: could standardization
lead to improved utilization of imaging within the diagnostic pathway?
J Magn Reson Imaging. 2013;37(1):48-58.
Rasch C, Barillot I, Remeijer P, Touw A, van Herk M, Lebesque JV. Definition of the prostate in CT and MRI: a multi-observer study. Int J
Radiat Oncol Biol Phys. 1999;43(1):57-66.
Zhong H, Kim JP, Chetty IJ. Analysis of deformable image registration
accuracy using computational modeling. Med Phys. 2010;37(3):970979.
Zhong H, Wen N, Gordon JJ, Elshaikh MA, Movsas B, Chetty IJ. An
adaptive MR-CT registration method for MRI-guided prostate cancer
radiotherapy. Phys Med Biol. 2015;60(7):2837-2851.
Li S, Glide-Hurst C, Lu M, et al. Voxel-based statistical analysis of uncertainties associated with deformable image registration. Phys Med Biol.
2013;58(18):6481-6494.
Bagher-Ebadian H, Janic B, Liu C, et al. Detection of dominant intraprostatic lesions in patients with prostate cancer using an artificial
neural network and MR multimodal radiomics analysis. Front Oncol.
2019;9:1313.
Klein S, Staring M, Murphy K, Viergever MA, Pluim JP. Elastix: a toolbox for intensity-based medical image registration. IEEE Trans Med
Imaging. 2010;29(1):196-205.
Shamonin DP, Bron EE, Lelieveldt BP, Smits M, Klein S, Staring M. Fast
parallel image registration on CPU and GPU for diagnostic classification of Alzheimer’s disease. Front Neuroinform. 2014;7:50.
Kim J, Glide-Hurst C, Doemer A, Wen N, Movsas B, Chetty IJ. Implementation of a novel algorithm for generating synthetic CT images
from magnetic resonance imaging data sets for prostate cancer radiation therapy. Int J Radiat Oncol Biol Phys. 2015;91(1):39-47.
Kim JP, Garbarino K, Schultz L, et al. Dosimetric evaluation of synthetic
CT relative to bulk density assignment-based magnetic resonanceonly approaches for prostate radiotherapy. Radiat Oncol. 2015;10:239.
Monninkhof EM, van Loon JWL, van Vulpen M, et al: Standard whole
prostate gland radiotherapy with and without lesion boost in prostate
cancer: Toxicity in the FLAME randomized controlled trial. Radiother
Oncol. 2018;127(1):74-80
Bentzen SM, Constine LS, Deasy JO, et al. Quantitative analyses of normal tissue effects in the clinic (QUANTEC): an introduction to the scientific issues. Int J Radiat Oncol Biol Phys. 2010;76(3 suppl):S3-S9.
Lee WR et al. RTOG 0415: A phase III randomized study of
hypofractionated 3D-CRT/IMRT versus conventionally fractionated
3D-CRT/IMRT in patients with favorable risk prostate cancer. 2008.
Allen Li X, Alber M, Deasy JO et al. The use and QA of biologically related models for treatment planning: Short report of the
TG-166 of the therapy physics committee of the AAPM. Med Phys.
2012;39(3):1386-1409.

126

20. Burman C, Kutcher G, Emami B, Goitein M. Fitting of normal tissue
tolerance data to an analytic function. Int J Radiat Oncol Biol Phys.
1991;21(1):123-135.
21. Wang JZ, Guerrero M, Li XA. How low is the α/β ratio for prostate cancer? Int J Radiat Oncol Biol Phys. 2003;55(1):194-203.
22. Fowler J, Chappell R, Ritter M. Is α/β for prostate tumors really low? Int
J Radiat Oncol Biol Phys. 2001;50(4):1021-1031.
23. Hanks G, Martz K, Diamond J. The effect of dose on local control of
prostate cancer. Int J Radiat Oncol Biol Phys. 1988;15(6):1299-1305.
24. Vogelius IR, Bentzen SM. Meta-analysis of the alpha/beta ratio for
prostate cancer in the presence of an overall time factor: bad news,
good news, or no news? Int J Radiat Oncol Biol Phys. 2013;85(1):8994.
25. Glazer DI, Hassanzadeh E, Fedorov A, et al. Diffusion-weighted
endorectal MR imaging at 3T for prostate cancer: correlation with
tumor cell density and percentage Gleason pattern on whole mount
pathology. Abdom Radiol. 2017;42(3):918-925.
26. Casares-Magaz O, Van der Heide UA, Rørvik J, Steenbergen P, Muren
LP. A tumour control probability model for radiotherapy of prostate
cancer using magnetic resonance imaging-based apparent diffusion
coefficient maps. Radiother Oncol. 2016;119(1):111-116.
27. Gao M, Mayr NA, Huang Z, Zhang H, Wang JZ. When tumor repopulation starts? The onset time of prostate cancer during radiation therapy.
Acta Oncologica. 2010;49(8):1269-1275.
28. Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991;21(1):109-122.
29. Nutting CM, Corbishley CM, Sanchez-Nieto B, Cosgrove VP, Webb
S, Dearnaley DP. Potential improvements in the therapeutic ratio of
prostate cancer irradiation: dose escalation of pathologically identified tumour nodules using intensity modulated radiotherapy. Br J
Radiol. 2002;75(890):151-161.
30. Bauman G, Haider M, Van der Heide UA, Menard C. Boosting imaging defined dominant prostatic tumors: A systematic review. Radiother
Oncol. 2013;107(3):274-281.
31. Schild MH, Schild SE, Wong WW, et al. A prospective trial of intensity modulated radiation therapy (IMRT) incorporating a simultaneous integrated boost for prostate cancer: long-term outcomes compared with standard image guided IMRT. Int J Radiat Oncol Biol Phys.
2017;97(5):1021-1025.
32. Schild MH, Schild SE, Wong WW, et al. Early outcome of prostate
intensity modulated radiation therapy (IMRT) incorporating a
simultaneous intra-prostatic MRI directed boost. OMICS J Radiol.
2014;3(4):170.
33. Murray LJ, Lilley J, Thompson CM, et al. Prostate stereotactic ablative
radiation therapy using volumetric modulated arc therapy to dominant intraprostatic lesions. Int J Radiat Oncol Biol Phys. 2014;89(2):406415.
34. Dowling JA, Lambert J, Parker J, et al. An atlas-based electron density
mapping method for magnetic resonance imaging (MRI)-alone treatment planning and adaptive MRI-based prostate radiation therapy. Int
J Radiat Oncol Biol Phys. 2012;83(1):e5-e11.

DUMAS ET AL .

35. Kraus KM, Jäkel O, Niebuhr NI, Pfaffenberger A. Generation of synthetic CT data using patient specific daily MR image data and image
registration. Phys Med Bio. 2017;62(4):1358-1377.
36. Lui L, Lei Y, Wang Y, et al. Evaluation of a deep learning-based pelvic
synthetic CT generation technique for MRI-based prostate proton
treatment planning. Phys Med Biol. 2019; 64:205022.
37. Chin AL, Lin A, Anamalayil S, Teo BKK. Feasibility and limitations of
bulk density assignment in MRI for head and neck IMRT treatment
planning. J Appl Clin Med Phys. 2014;15(5):4851.
38. Lambert J, Greer PB, Menk F, et al. MRI-guided prostate radiation
therapy planning: investigation of dosimetric accuracy of MRI-based
dose planning. Radiother Oncol. 2011;98(3):330-334.
39. Haustermans KM, Hofland I, Van Poppel H, et al. Cell kinetic measurements in prostate cancer. Int J Radiat Oncol Biol Phys. 1997;37(5):10671070.
40. Withers H, Taylor J, Maciejewski B. The hazard of accelerated
tumor clonogen repopulation during radiotherapy. Acta Oncol.
1988;27(2):131-146.
41. Lai P, Pilepich M, Krall J, et al. The effect of overall treatment time
on the outcome of definitive radiotherapy for localized prostate carcinoma: the Radiation Therapy Oncology Group 75-06 and 77-06 experience. Int J Radiat Oncol Biol Phys. 1991;21(4):925-933.
42. Perez CA, Michalski J, Mansur D, Lockett MA. Impact of elapsed treatment time on outcome of external-beam radiation therapy for localized carcinoma of the prostate. Cancer J. 2004;10(6):349-356.
43. Fowler JF, Ritter MA. A rationale for fractionation for slowly proliferating tumors such as prostatic adenocarcinoma. Int J Radiat Oncol Biol
Phys. 1995;32(2):521-529.
44. De Meerleer G, Villeirs G, Bral S, et al. The magnetic resonance detected intraprostatic lesion in prostate cancer: planning
and delivery of intensity-modulated radiotherapy. Radiother Oncol.
2005;75(3):325-333.
45. Rosenkrantz AB, Deng F-M, Kim S, et al. Prostate cancer: multiparametric MRI for index lesion localization—a multiple-reader study. AJR
Am J Roentgenol. 2012;199(4):830-837.
46. Russo F, Regge D, Armando E, et al. Detection of prostate cancer index
lesions with multiparametric magnetic resonance imaging (mp-MRI)
using whole-mount histological sections as the reference standard.
BJU Int. 2016;118(1):84-94.

How to cite this article: Dumas M, Leney M, Kim J, et al.
Magnetic resonance imaging-only-based radiation treatment
planning for simultaneous integrated boost of multiparametric
magnetic resonance imaging-defined dominant intraprostatic
lesions. Prec Radiat Oncol. 2022;6:119–126.
https://doi.org/10.1002/pro6.1152

